Article
Prognostic impact and immunogenicity of a novel osteosarcoma antigen, papillomavirus binding factor, in patients with osteosarcoma.
Cancer science - 1 Feb 2008
Tsukahara Tomohide, Kawaguchi Satoshi, Torigoe Toshihiko, Kimura Shigeharu, Murase Masaki, Ichimiya Shingo, Wada Takuro, Kaya Mitsunori, Nagoya Satoshi, Ishii Takeshi, Tatezaki Shin-ichiro, Yamashita Toshihiko, Sato Noriyuki
Abstract excerpt
To develop peptide-based immunotherapy for osteosarcoma, we previously identified papillomavirus binding factor (PBF) as a cytotoxic T lymphocytes (CTL)-defined osteosarcoma antigen in the context of human leukocyte antigen (HLA)-B55. In the present study, we analyzed the distribution profile of PBF in 83 biopsy specimens of osteosarcomas and also the prognostic impact of PBF expression in 78 patients with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.